PB CPD Online e-learning site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
 QUICK SEARCH:   [advanced]


     


Psychiatric Bulletin (1998) 22: 12-14. doi: 10.1192/pb.22.1.12
© 1998 The Royal College of Psychiatrists
This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murphy, B.
Right arrow Articles by Paton, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Murphy, B.
Right arrow Articles by Paton, C.

Maintenance doses for clozapine

Bernadette Murphy, Senior Registrar in Psychiatry, Colm Long, Senior House Officer in Psychiatry and Carol Paton, Principal Pharmacist*

Oxleas NHS Trust, Bexley Hospital, Old Bexley Lane, Bexley, Kent DA5 2BW

* Correspondence

The British National Formulary (BNF) entry for clozapine clearly distinguishes the treatment dose (200-450 mg daily, maximum 900 mg) from the maintenance dose (150-300 mg daily). We looked at 44 patients maintained on clozapine locally and found that 36 (82%) received doses above the BNF guidelines. This has considerable cost implications. While it is always good practice to maintain patients on the lowest possible dose of antipsychotic, the BNF guidelines are not based on objective outcome data, and should be treated cautiously.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1998 The Royal College of Psychiatrists.